TITLE

Prediction and Identification of Potential Immunodominant Epitopes in Glycoproteins B, C, E, G, and I of Herpes Simplex Virus Type 2

AUTHOR(S)
Mingjie Pan; Xingsheng Wang; Jianmin Liao; Dengke Yin; Suqin Li; Ying Pan; Yao Wang; Guangyan Xie; Shumin Zhang; Yuexi Li
PUB. DATE
January 2012
SOURCE
Clinical & Developmental Immunology;2012, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Twenty B candidate epitopes of glycoproteins B (gB2), C (gC2), E (gE2), G (gG2), and I (gI2) of herpes simplex virus type 2 (HSV-2) were predicted using DNAstar, Biosun, and Antheprot methods combined with the polynomial method. Subsequently, the biological functions of the peptides were tested via experiments in vitro. Among the 20 epitope peptides, 17 could react with the antisera to the corresponding parent proteins in the EIA tests. In particular, five peptides, namely, gB2466-473 (EQDRKPRN), gC2216-223 (GRTDRPSA), gE2483-491 (DPPERPDSP), gG2572-579 (EPPDDDDS), and gI2286-295 (CRRRYRRPRG) had strong reaction with the antisera. All conjugates of the five peptides with the carrier protein BSA could stimulate mice into producing antibodies. The antisera to these peptides reacted strongly with the corresponding parent glycoproteins during theWestern Blot tests, and the peptides reacted strongly with the antibodies against the parent glycoproteins during the EIA tests. The antisera against the five peptides could neutralize HSV-2 infection in vitro, which has not been reported until now. These results suggest that the immunodominant epitopes screened using software algorithms may be used for virus diagnosis and vaccine design against HSV-2.
ACCESSION #
84745331

 

Related Articles

  • High-Level Expression of Glycoprotein D by a Dominant-Negative HSV-1 Virus Augments its Efficacy as a Vaccine against HSV-1 Infection. Lu, Zheming; Brans, Richard; Akhrameyeva, Natali V; Murakami, Nao; Xu, Ximing; Yao, Feng // Journal of Investigative Dermatology;May2009, Vol. 129 Issue 5, p1174 

    Using the T-REx (Invitrogen, Carlsbad, CA) gene switch technology, we previously generated a dominant-negative herpes simplex virus (HSV)-1 recombinant, CJ83193, capable of inhibiting its own replication as well as that of wild-type HSV-1 and HSV-2. It has been further demonstrated that CJ83193...

  • Herpes Simplex Virus 2 (HSV-2) Infected Cell Proteins Are among the Most Dominant Antigens of a Live-Attenuated HSV-2 Vaccine. Geltz, Joshua J.; Gershburg, Edward; Halford, William P. // PLoS ONE;Feb2015, Vol. 10 Issue 2, p1 

    Virion glycoproteins such as glycoprotein D (gD) are believed to be the dominant antigens of herpes simplex virus 2 (HSV-2). We have observed that mice immunized with a live HSV-2 ICP0- mutant virus, HSV-2 0ΔNLS, are 10 to 100 times better protected against genital herpes than mice immunized...

  • Live-Attenuated HSV-2 ICP0- Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine. Halford, William P.; Püschel, Ringo; Gershburg, Edward; Wilber, Andrew; Gershburg, Svetlana; Rakowski, Brandon // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To...

  • Vaccine antibodies correlated with protection against HSV-1. Shafer, Emily // Infectious Disease News;Jan2014, Vol. 27 Issue 1, p21 

    The article reports that antibodies to herpes simplex virus type 2 glycoprotein D correlated with protection against herpes simplex virus type 1, according to research by Robert Belshe and colleagues that was published in the 2013 issue of "The Journal of Infectious Diseases."

  • Virology: Back to the HSV drawing board. Molloy, Sheilagh // Nature Reviews Microbiology;Feb2012, Vol. 10 Issue 2, p82 

    The article discusses the glycoprotein D (Gd)-based vaccine field trial against the herpes simplex virus type 2 (HSV-2) which references the study "Efficacy results of a trial of a herpes simplex vaccine," by R. B. Belshe and colleagues in the 2012 issue of "New England Journal of Medicine."

  • Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1. Brans, Richard; Akhrameyeva, Natali V.; Feng Yao // Journal of Investigative Dermatology;Oct2009, Vol. 129 Issue 10, p2470 

    CJ9-gD is a novel herpes simplex virus (HSV) type 1 recombinant virus that is completely replication-defective, expresses high-levels of HSV-1 major antigen glycoprotein D (gD), and can function in trans to inhibit replication of wild-type HSV-1 and HSV-2 in co-infected cells. Here, we show that...

  • Pan-HSV-2 IgG Antibody in Vaccinated Mice and Guinea Pigs Correlates with Protection against Herpes Simplex Virus 2. Halford, William P.; Geltz, Joshua; Gershburg, Edward // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    We lack a correlate of immunity to herpes simplex virus 2 (HSV-2) that may be used to differentiate whether a HSV-2 vaccine elicits robust or anemic protection against genital herpes. This gap in knowledge is often attributed to a failure to measure the correct component of the adaptive immune...

  • Efficacy Results of a Trial of a Herpes Simplex Vaccine. Belshe, Robert B.; Leone, Peter A.; Bernstein, David I.; Wald, Anna; Levin, Myron J.; Stapleton, Jack T.; Gorfinkel, Iris; Morrow, Rhoda L. Ashley; Ewell, Marian G.; Stokes-Riner, Abbie; Dubin, Gary; Heineman, Thomas C.; Schulte, Joann M.; Deal, Carolyn D. // New England Journal of Medicine;1/5/2012, Vol. 366 Issue 1, p34 

    Background: Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not...

  • Influencia de las vías de inmunización mucosales sobre la protección contra herpes simple tipo 2 con el AFCo1 como adyuvante. Cabrera, Osmir; Cuello, Maribel; Thörn, Karolina; Lindqvist, Madelene; Lastre, Miriam; González, Elizabeth; Zayas, Caridad; Balboa, Julio; Romeo, Belkis; Sarandi, Ali M.; Pérez, Oliver // Revista VacciMonitor (Vacunología y Temas Afines);sep-dic2011, Vol. 20 Issue 3, p14 

    Mucosal vaccines are a promising strategy to induce mucosal protection. Herpes simplex virus type 2 is the commonest pathogens in the human transmitted by exposure at the genital mucosal surfaces. Many vaccine candidates against this pathogen have been evaluated; but they have not been...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics